Therapies are tailored according to the molecular sub-type, and improvement of survival outcomes, especially in ER-positive and HER2-dependent breast cancers, has been obtained by targeting key molecular players in each sub-type [6,7,8,9]. Here, ESR1 is linked to breast carcinoma.